Condition: Cystic Fibrosis · Sponsor: Spirovant Sciences, Inc.
This is a Phase 1/2 multicenter, open-label, single dose trial of SP-101 investigational gene therapy in adults with CF who are ineligible for or intolerant to CFTR modulator therapy.
This description comes directly from the study's public registry record.
Spirovant.ClinicalTrials · (267) 805-6747 · clinicaltrials@spirovant.com
Always discuss trial participation with your own doctor first.
| University of Kansas Medical Center | Kansas City, Kansas, United States | Recruiting |
| Boston Children's Hospital, Brigham & Women's Hospital | Boston, Massachusetts, United States | Recruiting |
| Columbia University | New York, New York, United States | Recruiting |
| Hospital at University of Pennsylvania | Philadelphia, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06526923